Efficacy and adverse effects of levonorgestrel-releasing intrauterine system in treatment of adenomyosis.
- Author:
Lifeng ZHANG
1
;
Hui YANG
2
;
Xinmei ZHANG
1
;
Zhengyun CHEN
1
Author Information
1. Department of Gynecology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
2. Hunan Maternal and Child Health Hospital, Changsha 410008, China.
- Publication Type:Journal Article
- MeSH:
Adenomyosis;
Female;
Humans;
Intrauterine Devices, Medicated;
adverse effects;
standards;
Levonorgestrel;
administration & dosage;
adverse effects;
standards;
Retrospective Studies
- From:
Journal of Zhejiang University. Medical sciences
2019;48(2):130-135
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the efficacy and adverse effects of levonorgestrel-releasing intrauterine system (Mirena) in the treatment of adenomyosis.
METHODS:The clinical data of 75 patients with adenomyosis who had Mirena insertion in Women's Hospital,Zhejiang University School of Medicine from September 2013 to December 2013 were retrospectively analyzed. The patients were followed up to 39 months. The efficacy and adverse effects were assessed.
RESULTS:Pictorial Blood Loss Assessment Chart (PBAC) scores were decreased significantly after Mirena insertion both in patients with menorrhea (118±13 vs. 29±33, <0.01) and normal menstruation (82±15 vs. 14±13, <0.01); the patients with menorrhea showed a more significant decrease in PBAC score than those with normal menstruation (90±35 vs. 69±19,<0.01). The visual analogue scale (VAS) score decreased significantly after Mirena insertion compared with pre-treatment[7(6,7) vs. 1(0,2), <0.01]. The expulsion of Mirena occurred in 18 cases (24.0%); 9 cases (12.0%) had no effect and 28 cases (37.3%) had changes of menstruation patterns. Multivariate Cox regression analysis showed that the expulsion of Mirena was not associated with post-treatment VAS score, PBAC score before and after treatment or menstrual stabilization time (all >0.05).
CONCLUSIONS:Mirena is effective and safe in the long term management of adenomyosis, but about one third patients may require further treatment because of the expulsion or ineffectiveness of Mirena.
